Microbiology and Immunology

You are here

Home > Publications > Publications

Publications

Found 59 results
Author Title Type [ Year(Asc)]
Filters: Author is Nathan, Carl F  [Clear All Filters]
2021
Zhang L, Jiang X, Pfau D, Ling Y, Nathan CF.  2021.  Type I interferon signaling mediates Mycobacterium tuberculosis-induced macrophage death.. J Exp Med. 218(2)
2019
Quezada LLopez, Silve S, Kelinske M, Liba A, Gonzalez CDiaz, Kotev M, Goullieux L, Sans S, Roubert C, Lagrange S et al..  2019.  Bactericidal Disruption of Magnesium Metallostasis in Mycobacterium tuberculosis Is Counteracted by Mutations in the Metal Ion Transporter CorA.. mBio. 10(4)
Wu J, Mu R, Sun M, Zhao N, Pan M, Li H, Dong Y, Sun Z, Bai J, Hu M et al..  2019.  Derivatives of Natural Product Agrimophol as Disruptors of Intrabacterial pH Homeostasis in .. ACS Infect Dis. 5(7):1087-1104.
Quezada LLopez, Li K, McDonald SL, Nguyen Q, Perkowski AJ, Pharr CW, Gold B, Roberts J, McAulay K, Saito K et al..  2019.  Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating .. ACS Infect Dis. 5(8):1433-1445.
Zimmerman M, McDonald SL, Ho-Liang H-P, Porubsky P, Nguyen Q, Pharr CW, Perkowski AJ, Smith R, Schoenen FJ, Gold BS et al..  2019.  Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma.. J Antibiot (Tokyo). 72(6):469-475.
Early J, Ollinger J, Darby C, Alling T, Mullen S, Casey A, Gold B, Ochoada J, Wiernicki T, Masquelin T et al..  2019.  Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.. ACS Infect Dis. 5(2):272-280.
Nathan CF, Nussenzweig MC, Pulvirenti T.  2019.  JEM Editorial Board: Expanding on the basis of cancer.. J Exp Med. 216(8):1725.
Zhan W, Hsu H-C, Morgan T, Ouellette T, Burns-Huang K, Hara R, Wright AG, Imaeda T, Okamoto R, Sato K et al..  2019.  Selective Phenylimidazole-Based Inhibitors of the Mycobacterium tuberculosis Proteasome.. J Med Chem. 62(20):9246-9253.
Mosior J, Bourland R, Soma S, Nathan C, Sacchettini J.  2019.  Structural insights into phosphopantetheinyl hydrolase PptH from Mycobacterium tuberculosis.. Protein Sci.
2018
Kirkman LA, Zhan W, Visone J, Dziedziech A, Singh PK, Fan H, Tong X, Bruzual I, Hara R, Kawasaki M et al..  2018.  Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.. Proc Natl Acad Sci U S A. 115(29):E6863-E6870.
Yu H, Lupoli TJ, Kovach A, Meng X, Zhao G, Nathan CF, Li H.  2018.  ATP hydrolysis-coupled peptide translocation mechanism of Mycobacterium tuberculosis ClpB.. Proc Natl Acad Sci U S A. 115(41):E9560-E9569.
McAulay K, Saito K, Warrier T, Walsh KFrances, Mathurin LDaniel, Royal-Mardi G, Lee MHee, Ocheretina O, Pape JWilliam, Fitzgerald DW et al..  2018.  Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.. mBio. 9(6)
Mundhra S, Bryk R, Hawryluk N, Zhang T, Jiang X, Nathan C.  2018.  Evidence for dispensability of protein kinase R in host control of tuberculosis.. Eur J Immunol. 48(4):612-620.
Negri A, Javidnia P, Mu R, Zhang X, Vendome J, Gold B, Roberts J, Barman D, Ioerger T, Sacchettini JC et al..  2018.  Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosis.. ACS Infect Dis. 4(5):771-787.
2017
Botella H, Yang G, Ouerfelli O, Ehrt S, Nathan CF, Vaubourgeix J.  2017.  Distinct Spatiotemporal Dynamics of Peptidoglycan Synthesis between Mycobacterium smegmatis and Mycobacterium tuberculosis.. mBio. 8(5)
Nathan C.  2017.  Introduction of Laurie H. Glimcher, MD.. J Clin Invest. 127(10):3575.
Nathan C, Nussenzweig MC, Pulvirenti T.  2017.  JEM Advisory Editorial Board: Increasing diversity.. J Exp Med.
Nathan C.  2017.  Kunkel Lecture: Fundamental immunodeficiency and its correction.. J Exp Med. 214(8):2175-2191.
Nathan C, Nussenzweig M, Pulvirenti T.  2017.  The new face of JEM.. J Exp Med. 214(12):3467.
Totaro KA, Barthelme D, Simpson PT, Jiang X, Lin G, Nathan C, Sauer RT, Sello JK.  2017.  Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.. ACS Infect Dis. 3(2):176-181.
Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J et al..  2017.  Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations.. Proc Natl Acad Sci U S A. 114(24):E4832-E4840.
Santos Rde Luna Al, Bai L, Singh PK, Murakami N, Fan H, Zhan W, Zhu Y, Jiang X, Zhang K, Assker JPierre et al..  2017.  Structure of human immunoproteasome with a reversible and noncompetitive inhibitor that selectively inhibits activated lymphocytes.. Nat Commun. 8(1):1692.
Gold B, Nathan C.  2017.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.. Microbiol Spectr. 5(1)
2016
Karreci ESula, Fan H, Uehara M, Mihali AB, Singh PK, Kurdi AT, Solhjou Z, Riella LV, Ghobrial I, Laragione T et al..  2016.  Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice.. Proc Natl Acad Sci U S A. 113(52):E8425-E8432.
Warrier T, Kapilashrami K, Argyrou A, Ioerger TR, Little D, Murphy KC, Nandakumar M, Park S, Gold B, Mi J et al..  2016.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.. Proc Natl Acad Sci U S A. 113(31):E4523-30.